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The analysis of in vitro cell senescence/growth after serial passaging can be one of ways to show the
absence of immortalized cells, which are frequently tumorigenic, in human cell-processed therapeutic
products (hCTPs). However, the performance of the cell growth analysis for detection of the immortal-
ized cellular impurities has never been evaluated. In the present study, we examined the growth rates of
human mesenchymal stem cells (hMSCs, passage 5 (P ¼ 5)) contaminated with various doses of HeLa
cells, and compared with that of hMSCs alone. The growth rates of the contaminated hMSCs were
comparable to that of hMSCs alone at P ¼ 5, but signiﬁcantly increased at P ¼ 6 (0.1% and 0.01% HeLa) or
P ¼ 7 (0.001% HeLa) within 30 days. These ﬁndings suggest that the cell growth analysis is a simple and
sensitive method to detect immortalized cellular impurities in hCTPs derived from human somatic cells.
© 2014 The Authors. Published by Elsevier Ltd on behalf of The International Alliance for Biological
Standardization. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/3.0/).1. Introduction
Human cell-processed therapeutic products (hCTPs) are ex-
pected to provide novel breakthrough therapies for currently life-
threatening or incurable diseases. In the clinical applications of
hCTPs to patients, however, one of the major concerns is the
tumorigenic cellular impurities in the products. Since pluripotent
stem cells (PSCs), such as embryonic stem cells and induced
pluripotent stem cells, are tumorigenic [1e3], there is a risk of tu-
mor formation if the products contain the residual undifferentiatede Therapy Products, National
aya, Tokyo 158-8501, Japan.
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by-nc-nd/3.0/).PSCs [4]. On the other hand, somatic cells are considered to have
little tumorigenic potential even after substantial manipulations
like in vitro expansion, because they consistently pass into senes-
cence [5]. Malignant transformation of the cells is believed to occur
through multiple processes involving the accumulation of muta-
tions in key regulatory genes that promote cell survival and pro-
liferation [6,7]. Although a few individual groups reported the
spontaneous transformation of human mesenchymal stem cells
(hMSCs) during in vitro culture [8e11], two of them retracted their
papers because the results appeared to be attributable to contam-
ination with tumorigenic cells (ﬁbrosarcoma, osteosarcoma, or
glioma cell lines) [12,13]. The rest of the groups found the immor-
talization of the cells, which is closely associated with tumorige-
nicity, during in vitro culture, indicating that the good practices to
avoid contamination with tumorigenic cells and the monitoring of
cell growth are critical for the quality control of hCTPs derived from
human somatic cells.lliance for Biological Standardization. This is an open access article under the CC BY-
Abbreviations
hCTP human cell-processed therapeutic product
PSC pluripotent stem cell
hMSC human mesenchymal stem cell
STR short tandem repeat
P ¼ n passage n
PBS phosphate buffered saline
RT room temperature
HPV human papillomavirus
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evaluated by the short tandem repeat (STR) analysis [14]. However,
the cell growth analysis which simply monitors the cell prolifera-
tion for a limited period may be adequately sensitive for the
detection of the contamination of somatic cells with immortalized/
tumorigenic cells, because somatic cells usually show slower
growth, compared with that of immortalized/tumorigenic cells, as
well as the attenuation of the growth after serial passaging [15e17].
In fact, the European Medicines Agency has considered that the
evaluation of in vitro cell senescence after serial passaging is suf-
ﬁcient to prove the absence of immortalized/tumorigenic cells in a
somatic cell-based product [18]. However, the performance of the
cell growth analysis for detection of the immortalized/tumorigenic
cellular impurities in somatic cells has never been studied. In the
present study, we examined the growth of hMSCs contaminated
with various doses of HeLa cells, a well-known cancer cell line, to
determine the sensitivity of the cell growth analysis for the
detection of the immortalized/tumorigenic cells in human somatic
cells.2. Materials and methods
2.1. Cells
hMSCs (Lonza, Walkersville, MD) at passage 2 (P ¼ 2) were
cultured in MSCGM BulletKit, a mesenchymal stem cell basal me-
diumwith mesenchymal cell growth supplement, L-glutamine, and
gentamycin/amphotericin-B (Lonza). HeLa cells (the Health Science
Research Resources Bank, Osaka, Japan) were maintained in Eagle's
minimum essential medium (Sigma), supplemented with 10% fetal
bovine serum (FBS; Sigma), 0.1 mM non-essential amino acids (Life
Technologies), 50 U/ml penicillin, and 50 mg/ml streptomycin (Life
Technologies). Cells were cultured in a humidiﬁed atmosphere of
5% CO2 and 95% air at 37 C, and were passaged upon reaching 90%
conﬂuence.2.2. Cell growth analysis
At P ¼ 5 of hMSCs, 1 106 of hMSCs were mixed with 1000, 100,
or 10 of HeLa cells and seeded into T175 ﬂasks (Corning). The cells
were maintained in 40 ml of Dulbecco's Modiﬁed Eagle's medium
(DMEM; Gibco) supplemented with 10% FBS, 50 U/ml penicillin,
and 50 mg/ml streptomycin. Upon reaching approximately 90%
conﬂuence, the cells were washed with phosphate buffered saline
(PBS) and treated with 0.05% trypsin-EDTA solution (Gibco) for
detachment from the ﬂasks. The cells were centrifuged at 450  g
for 5min and suspendedwith the fresh culturemedium. Aliquots of
the suspended cells were stained with Trypan Blue solution and
counted by Countess Automated Cell Counter (Invitrogen) accord-
ing to the manufacture's protocol. One million cells in thesuspension were re-seeded into T175 ﬂasks and cultured until the
next passage. This process was repeated by P ¼ 10. The growth rate
(Rn) at P ¼ n was calculated by the following equation:
Rn ¼ [log2(Nnþ1/Nn)]/(Dnþ1  Dn)
where Nk and Dk are the number of accumulated cells and the date
at P ¼ k, respectively.2.3. Immunoﬂuorescence microscopy
hMSCs contaminated with HeLa cells were ﬁxed with 4% para-
formaldehyde in PBS (Nacalai Tesque) for 10 min at room temper-
ature (RT) and blocked in Blocking One (Nacalai Tesque) for
30 min at RT. The cells, then, were incubated with anti-HPV18 E7
antibody (8E2) (abcam) diluted at 1:500 in the blocking solution
(PBS containing 5% Blocking One) for 1 h at RT for primary staining,
and secondarily stained with goat anti-mouse IgG Alexa Fluor 488
(1:1000; Invitrogen) in the blocking solution for 45 min at RT. The
cells were mounted with VECTASGIELD mounting medium with
DAPI (VECTOR) and observed with a ﬂuorescencemicroscope (IX71,
Olympus).3. Results and discussion
In the present study, we added 1000, 100, or 10 of HeLa cells to
1  106 of hMSCs of passage 5 (P ¼ 5) and compared their growth
with that of hMSCs alone (HeLa 0) until P ¼ 10. The growth curves
of three lots of hMSCs and the contaminated hMSCs are shown in
Fig. 1. The cell numbers of HeLa 0 and the contaminated hMSCs
were comparable at P ¼ 5. The growth of HeLa 0 was constant
during the early culture and getting slower with time (Fig. 1), while
the growth of the contaminated cells was accelerated.
To conﬁrm that the increases in the growth were attributable to
the contamination with HeLa cells, we observed the cells with
phase contrast microscopy. In the images of the contaminated
hMSCs, we found small cells clearly different from hMSCs (Fig. 2A),
and their relative abundance increased every passage. Because
HeLa cells are infected with human papillomaviruses (HPV), we
performed immunoﬂuorescence analysis using HPV18 E7 antibody
and conﬁrmed that the cells were HeLa cells not transformed
hMSCs (Fig. 2B). At P ¼ 10, hMSCs were hardly identiﬁed in images
of HeLa 1000 (Fig. 2C), because almost all of hMSCswere exchanged
for HeLa cells at the ﬁve passages.
Next, we examined the growth rates of the contaminated cells
(Fig. 3A). They were comparable to that of HeLa 0 at P ¼ 5, and got
signiﬁcantly increased at P ¼ 6 (HeLa 1000 and HeLa 100) or P ¼ 7
(HeLa 10). These results indicated that the gross proliferation rate
was not inﬂuenced by the spiked cells at P ¼ 5 and then the pop-
ulation of HeLa cells in hMSCs increased in dose- and time-
dependent manner. Eventually, the growth rate (doubling/day) of
the contaminated hMSCs increased, and then reached plateau. The
average growth rate of the contaminated cells at P ¼ 9 and 10 was
0.73, suggesting that the growth rate of HeLa cells was approxi-
mately 0.7 in this culture condition. The average growth rates of the
three lots are plotted along the passage number in Fig. 3B. The
growth rates of HeLa 1000 and HeLa 100 at P ¼ 7 and HeLa
10 at P ¼ 8 were signiﬁcantly increased compared with the growth
rates at P ¼ 5 (*P < 0.05, two-way repeated measures ANOVA and
Student-NewmaneKeulis test). These results indicate that the cell
cultures longer than P¼ 7 (about 20 days) and P¼ 8 (about 30 days)
detect cross-contaminations of 100 (0.01%) and 10 (0.001%) HeLa
cells, respectively, assuming that 106 hMSCs were contaminated at
P ¼ 5.
Fig. 1. Cell growth analysis of hMSCs contaminated with HeLa cells. At the passage 5 (P ¼ 5) of hMSCs, 1  106 of hMSCs were mixed with 0, 10, 100, or 1000 of HeLa cells (HeLa 0,
HeLa 10, HeLa 100, or HeLa 1000). Cells were passaged and counted at the indicated day from P ¼ 5. The results of three lots of hMSCs are presented (Lot 1, 2, and 3).
K. Kono et al. / Biologicals 43 (2015) 146e149148The tumorigenicity has been evaluated by in vitro assays (e.g.,
soft agar formation assay, karyotype analysis) and/or in vivo assays
(transplantation into immunodeﬁcient animals) [8,9,19,20]. When
these assays are performed to detect a trace amount of tumorigenic
cells in hCTPs, they need to be of high sensitivity. Recently, we
developed a highly sensitive in vivo tumorigenicity test using
severely immunocompromised mice, NOG mice, in combination
with Matrigel. Subcutaneous transplantation into NOG mice with
Matrigel allowed inoculation with 1  107 cells and actually ach-
ieved detection of 0.002% HeLa cells spiked into hMSCs in a half of
the mice (unpublished data). However, in vivo tumorigenicity testFig. 2. Phase contrast and immunoﬂuorescence microscopy of hMSCs contaminated with
presented. Red arrow pointed at the small size cells which were clearly different from hMS
conducted by using anti-HPV E7 antibody. Green: Alexa Fluor 488 goat anti-mouse IgG; blusing immunodeﬁcient animals requires a speciﬁc facility, and
takes 3e4 months. In contrast, the cell growth analysis is not only
simple and economical, but also detects as few as 0.001% immortal
cellular impurities in hMSCs within 30 days, in case that the growth
properties of the immortal cells are comparable to those of HeLa
cells. Although immortality does not necessarily indicate tumori-
genicity, it is known to be closely associated with cell trans-
formation in many cases of tumorigenesis. Therefore, the present
study can be said to be the ﬁrst scientiﬁc basis for the usefulness of
the cell growth analysis as one of tumorigenicity tests for hCTPs
derived from human somatic cells.HeLa cells. (A) Representative image of the contaminated cells (HeLa 100 at P ¼ 8) is
Cs. (B) Phase contrast and immunoﬂuorescence microscopy of HeLa 1000 at day 5 was
ue: DAPI. (C) Representative image of HeLa 1000 at P10 is presented.
Fig. 3. Cell growth rate analysis of hMSCs contaminated with HeLa cells. (A) The Y-axis
indicates the growth rate (doubling per day) of hMSCs. The results of three lots of hMSCs
are presented (Lot 1, 2, and 3). (B) The growth rates of three lots of hMSCs are plotted
along the passage numbers. Data are represented as mean ± S.E.M. of the three lots.
Statistical signiﬁcance was determined using two-way repeated measures ANOVA and
Student-NewmaneKeulis's post-hoc test (*P < 0.05 compared with the rate at P ¼ 5).
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